In addition, MSC‐1/AZD0171 neutralizing LIF mAb, although in Phase 2 combined human clinical trial (NCT049999690), is primarily intended for the treatment of metastatic pancreatic cancer, and there is still a lack of effective small molecule inhibitors for cytoplasmic LIF in HCC. Here, LIF is linked to familial pancreatic carcinoma.